Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high ...

Jonah Hill's dramatic weight loss didn't just change his body, it noticeably altered his face, leaving behind a gaunt look ...

Learn more about GLP-1 pills and how they may be more convenient and cost-effective than the injections.

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about amylin analogs, retatrutide and more.

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit ...

Novo Nordisk won't add Alzheimer's disease to the list of conditions its blockbuster diabetes and weight-loss drugs, Ozempic and Wegovy, can treat, despite high hopes and two years of study. The ...

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

Novo Nordisk’s ‘There’s Only One Ozempic’ campaign is about reasserting the drugmaker’s brand name in an increasingly ...

Here’s what the science says.

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

Donald Trump’s threat to impose fresh tariffs on his European allies unless Denmark agrees to sell Greenland is further proof that the world cannot afford to base policy on what the U.S. president may ...